NKTR Stock Summary

• Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; merely 7.8% of US stocks have a lower such ratio.
• NKTR's price/sales ratio is 27.18; that's higher than the P/S ratio of 96.04% of US stocks.
• Revenue growth over the past 12 months for Nektar Therapeutics comes in at -91.33%, a number that bests merely 0.79% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to Nektar Therapeutics, a group of peers worth examining would be NVAX, MGNX, ARDS, UMRX, and INO.
• Visit NKTR's SEC page to see the company's official filings. To visit the company's web site, go to www.nektar.com.